# Biotech Daily Digest ‚Äî 2026-02-20

**29 items from 4 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 6 items
- MHRA ‚Äì News: 1 item
- arXiv q-bio: 15 items


## Endpoints News

- **[Daiichi taps John Tsai to lead R&D as Ken Takeshita departs](https://endpoints.news/daiichi-taps-john-tsai-to-lead-rd-as-ken-takeshita-departs/)**  
  _Fri, 20 Feb 2026 14:38:30 +0000_  
  John Tsai, a former chief medical officer at Novartis and Amgen, will steer Daiichi Sankyo's global R&D efforts starting April 1.

 He'll take over from Ken Takeshita, who is stepping down ...

- **[Novartis to divest India unit to private equity-led consortium for $159M](https://endpoints.news/novartis-to-divest-india-unit-to-private-equity-led-consortium-for-159m/)**  
  _Fri, 20 Feb 2026 12:15:13 +0000_  
  Novartis is selling its majority stake in its generics and prescription business in India to a consortium of private equity firms, stemming from a strategic review the Swiss pharma announced in ...

- **[Sanofi appoints specialty care head; Biogen chair to retire in June](https://endpoints.news/sanofi-appoints-specialty-care-head-biogen-chair-to-retire-in-june/)**  
  _Fri, 20 Feb 2026 12:00:30 +0000_  
  ‚Üí As Sanofi looks ahead to the Bel√©n Garijo era, the French pharma will also have a new head of specialty care on March 1. Brian Foard

- **[FDA formalizes one pivotal trial policy via NEJM perspective](https://endpoints.news/fda-formalizes-one-pivotal-trial-policy-via-nejm-perspective/)**  
  _Thu, 19 Feb 2026 16:47:54 +0000_  
  Top FDA officials said that a single pivotal trial requirement will be the ‚Äúnew default standard‚Äù for drug approvals, a move that goes beyond the agency‚Äôs prior discretion around not requiring two trials.

 In a ...

- **[Obesity biotech Verdiva plans big year of data, explores deals](https://endpoints.news/obesity-biotech-verdiva-plans-big-year-of-data-explores-deals/)**  
  _Thu, 19 Feb 2026 16:47:40 +0000_  
  Pfizer‚Äôs purchase of obesity biotech Metsera last year threw the spotlight on long-acting weight loss drugs. And the launch of Novo Nordisk‚Äôs Wegovy pill in January did the same ...

- **[Biogen stops part of an MS trial; Merck reports more Enflonsia data](https://endpoints.news/biogen-stops-part-of-an-ms-trial-merck-reports-more-enflonsia-data/)**  
  _Thu, 19 Feb 2026 15:55:48 +0000_  
  Plus, news about Compass Pathways, Starget Pharma and Ten63 Therapeutics:

 üõë Biogen halts combo portion of MS trial: The biotech is not moving forward with the second part of the

- **[Sanofi to expand in India; Stada invests $100M in Saudi¬†Arabia](https://endpoints.news/sanofi-to-expand-in-india-stada-invests-100m-in-saudi/)**  
  _Thu, 19 Feb 2026 15:42:43 +0000_  
  Sanofi is further boosting its presence in India with an expansion of its Global Capability Centre in Hyderabad. The move will add 1,900 new jobs, which will bring the total number ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-roche-taps-aussie-oncologist-lead-early-research" hreflang="en">Chutes &amp; Ladders‚ÄîRoche taps Aussie oncologist to lead early research</a>](https://www.fiercebiotech.com/biotech/chutes-ladders-roche-taps-aussie-oncologist-lead-early-research)**  
  _Feb 19, 2026 4:51pm_  
  The Swiss drugmaker has plucked an experienced scientist from Down Under to lead its early research efforts. Hematologist Mark Dawson, M.D., Ph.D., an expert in cancer epigenetics, will now head up Roche‚Äôs pharma research and early development unit, effective May 1.

- **[<a href="https://www.fiercebiotech.com/medtech/mainz-biomed-snares-6m-private-placement-looks-shed-coloalert" hreflang="en">Mainz Biomed looks to shed ColoAlert, shifts focus in US</a>](https://www.fiercebiotech.com/medtech/mainz-biomed-snares-6m-private-placement-looks-shed-coloalert)**  
  _Feb 20, 2026 7:36am_  
  Mainz Biomed, maker of the ColoAlert test, inked a private placement deal for $6 million and is looking to shed its colorectal cancer assets as it shifts its focus to building a pancreatic cancer detection program in the U.S.

- **[<a href="https://www.fiercebiotech.com/biotech/daiichi-picks-former-novartis-cmo-john-tsai-head-rd" hreflang="en">Daiichi picks former Novartis CMO John Tsai to head up R&amp;D</a>](https://www.fiercebiotech.com/biotech/daiichi-picks-former-novartis-cmo-john-tsai-head-rd)**  
  _Feb 20, 2026 4:57am_  
  Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai, M.D., has taken up a similar role at Daiichi Sankyo.

- **[<a href="https://www.fiercebiotech.com/biotech/novartis-dropped-ph-1-solid-tumor-candidate-showed-complete-lack-efficacy" hreflang="en">Novartis winds down ph. 1 solid tumor program after lacking efficacy</a>](https://www.fiercebiotech.com/biotech/novartis-dropped-ph-1-solid-tumor-candidate-showed-complete-lack-efficacy)**  
  _Feb 19, 2026 2:12pm_  
  Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease.

- **[<a href="https://www.fiercebiotech.com/biotech/white-house-frustration-may-have-fueled-fdas-moderna-change-politico" hreflang="en">White House frustration may have fueled FDA‚Äôs Moderna walkback: Politico </a>](https://www.fiercebiotech.com/biotech/white-house-frustration-may-have-fueled-fdas-moderna-change-politico)**  
  _Feb 19, 2026 11:33am_  
  Politico has reported that the White House isn‚Äôt happy with the FDA‚Äôs recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator.

- **[<a href="https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy" hreflang="en">J&amp;J halts enrollment in phase 2 trial of AC Immune-partnered Alzheimer's therapy</a>](https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy)**  
  _Feb 19, 2026 9:11am_  
  Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer‚Äôs disease candidate, leaving analysts to speculate that recruitment challenges may be the culprit.


## MHRA ‚Äì News

- **[Transparency data: MHRA Performance Data](https://www.gov.uk/government/publications/mhra-performance-data)**  
  _2026-02-20T10:21:14Z_  
  Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.


## arXiv q-bio

- **[Tracing protein and proteome history with chronologies and networks: folding recapitulates evolution](https://arxiv.org/abs/2602.16724)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16724v1 Announce Type: new 
Abstract: Introduction: While the origin and evolution of proteins remain mysterious, advances in evolutionary genomics and systems biology are facilitating the historical exploration of the structure, function and organization of proteins and proteomes. Molecular chronologies ar‚Ä¶

- **[FUNGAR: a pipeline for detecting antifungal resistance mutations directly from metagenomic short reads](https://arxiv.org/abs/2602.16728)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16728v1 Announce Type: new 
Abstract: Motivation: Antifungal resistance has become an increasing global concern in both clinical and environmental health. Detecting known resistance mutations directly from sequencing reads, in special metagenomic samples, remains a major challenge. As fungal pathogens are o‚Ä¶

- **[Exploring the Utility of MALDI-TOF Mass Spectrometry and Antimicrobial Resistance in Hospital Outbreak Detection](https://arxiv.org/abs/2602.16737)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16737v1 Announce Type: new 
Abstract: Accurate and timely identification of hospital outbreak clusters is crucial for preventing the spread of infections that have epidemic potential. While assessing pathogen similarity through whole genome sequencing (WGS) is considered the gold standard for outbreak detec‚Ä¶

- **[Re-Solving the Shepherding Problem: Lead When Possible, Herd When Necessary](https://arxiv.org/abs/2602.16750)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16750v1 Announce Type: new 
Abstract: Designing systems for autonomous transport of groups of living agents has received a lot of attention in recent years due to a wealth of important potential applications. Biomimetic approaches are often sought, and a range of herding algorithms, inspired by how dogs her‚Ä¶

- **[PREFER: An Ontology for the PREcision FERmentation Community](https://arxiv.org/abs/2602.16755)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16755v1 Announce Type: new 
Abstract: Precision fermentation relies on microbial cell factories to produce sustainable food, pharmaceuticals, chemicals, and biofuels. Specialized laboratories such as biofoundries are advancing these processes using high-throughput bioreactor platforms, which generate vast d‚Ä¶

- **[Spatio-temporal air flow properties in a 3D personalised model of the human lung](https://arxiv.org/abs/2602.17265)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17265v1 Announce Type: new 
Abstract: We propose a multi-scale lung model to investigate spatio-temporal distributions of ventilation variables. Lung envelope and large airway geometries are derived from CT scans; smaller airways are generated using a physiologically consistent algorithm. Tissue mechanics i‚Ä¶

- **[Systematic Evaluation of Single-Cell Foundation Model Interpretability Reveals Attention Captures Co-Expression Rather Than Unique Regulatory Signal](https://arxiv.org/abs/2602.17532)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17532v1 Announce Type: new 
Abstract: We present a systematic evaluation framework - thirty-seven analyses, 153 statistical tests, four cell types, two perturbation modalities - for assessing mechanistic interpretability in single-cell foundation models. Applying this framework to scGPT and Geneformer, we f‚Ä¶

- **[Probability-Invariant Random Walk Learning on Gyral Folding-Based Cortical Similarity Networks for Alzheimer's and Lewy Body Dementia Diagnosis](https://arxiv.org/abs/2602.17557)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17557v1 Announce Type: new 
Abstract: Alzheimer's disease (AD) and Lewy body dementia (LBD) present overlapping clinical features yet require distinct diagnostic strategies. While neuroimaging-based brain network analysis is promising, atlas-based representations may obscure individualized anatomy. Gyral fo‚Ä¶

- **[Construction of a classification model for dementia among Brazilian adults aged 50 and over](https://arxiv.org/abs/2602.16887)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.16887v1 Announce Type: cross 
Abstract: To build a dementia classification model for middle-aged and elderly Brazilians, implemented in Python, combining variable selection and multivariable analysis, using low-cost variables with modification potential. Observational study with a predictive modeling approa‚Ä¶

- **[JEPA-DNA: Grounding Genomic Foundation Models through Joint-Embedding Predictive Architectures](https://arxiv.org/abs/2602.17162)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17162v1 Announce Type: cross 
Abstract: Genomic Foundation Models (GFMs) have largely relied on Masked Language Modeling (MLM) or Next Token Prediction (NTP) to learn the language of life. While these paradigms excel at capturing local genomic syntax and fine-grained motif patterns, they often fail to captu‚Ä¶

- **[Geometric and topological constraints on oral seal formation during infant breastfeeding](https://arxiv.org/abs/2602.17389)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17389v1 Announce Type: cross 
Abstract: Breastfeeding efficiency relies on coordinated tongue motion, sustained tissue contact and maintenance of an effective intraoral seal. Current assessments of seal formation mainly use local kinematic descriptors or pressure recordings, which do not capture the global‚Ä¶

- **[On structural contraction of biological interaction networks](https://arxiv.org/abs/2307.13678)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2307.13678v4 Announce Type: replace-cross 
Abstract: Biological networks are customarily described as structurally robust. This means that they often function extremely well under large forms of perturbations affecting both the concentrations and the kinetic parameters. In order to explain this property, various‚Ä¶

- **[Data Augmentation Scheme for Raman Spectra with Highly Correlated Annotations](https://arxiv.org/abs/2402.00851)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2402.00851v2 Announce Type: replace-cross 
Abstract: In biotechnology Raman Spectroscopy is rapidly gaining popularity as a process analytical technology (PAT) that measures cell densities, substrate- and product concentrations. As it records vibrational modes of molecules it provides that information non-invasi‚Ä¶

- **[Inferring entropy production in many-body systems using nonequilibrium maximum entropy](https://arxiv.org/abs/2505.10444)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2505.10444v4 Announce Type: replace-cross 
Abstract: We propose a method for inferring entropy production (EP) in high-dimensional stochastic systems, including many-body systems and non-Markovian systems with long memory. Standard techniques for estimating EP become intractable in such systems due to computatio‚Ä¶

- **[AtlasPatch: Efficient Tissue Detection and High-throughput Patch Extraction for Computational Pathology at Scale](https://arxiv.org/abs/2602.03998)**  
  _Fri, 20 Feb 2026 00:00:00 -0500_  
  arXiv:2602.03998v2 Announce Type: replace-cross 
Abstract: Whole-slide image (WSI) preprocessing, comprising tissue detection followed by patch extraction, is foundational to AI-driven computational pathology but remains a major bottleneck for scaling to large and heterogeneous cohorts. We present AtlasPatch, a scalab‚Ä¶
